JP2019513821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513821A5 JP2019513821A5 JP2019502538A JP2019502538A JP2019513821A5 JP 2019513821 A5 JP2019513821 A5 JP 2019513821A5 JP 2019502538 A JP2019502538 A JP 2019502538A JP 2019502538 A JP2019502538 A JP 2019502538A JP 2019513821 A5 JP2019513821 A5 JP 2019513821A5
- Authority
- JP
- Japan
- Prior art keywords
- serotype
- polypeptide
- item
- group
- unique
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 270
- 230000002163 immunogen Effects 0.000 claims description 183
- 239000000203 mixture Substances 0.000 claims description 168
- 239000008194 pharmaceutical composition Substances 0.000 claims description 142
- 150000004676 glycans Chemical class 0.000 claims description 141
- 229920001282 polysaccharide Polymers 0.000 claims description 139
- 239000005017 polysaccharide Substances 0.000 claims description 139
- 239000012634 fragment Substances 0.000 claims description 121
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 100
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 100
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 92
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 92
- 239000000872 buffer Substances 0.000 claims description 24
- 239000002671 adjuvant Substances 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 14
- 241000606768 Haemophilus influenzae Species 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000007972 injectable composition Substances 0.000 claims description 10
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 230000003571 opsonizing effect Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 108010059574 C5a peptidase Proteins 0.000 claims description 5
- 101100263205 Coxiella burnetii (strain RSA 493 / Nine Mile phase I) uspA2 gene Proteins 0.000 claims description 5
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 5
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 claims description 5
- 102000004895 Lipoproteins Human genes 0.000 claims description 5
- 108090001030 Lipoproteins Proteins 0.000 claims description 5
- 102000015636 Oligopeptides Human genes 0.000 claims description 5
- 108010038807 Oligopeptides Proteins 0.000 claims description 5
- 201000005702 Pertussis Diseases 0.000 claims description 5
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 claims description 5
- 101710183389 Pneumolysin Proteins 0.000 claims description 5
- 101710188053 Protein D Proteins 0.000 claims description 5
- 101710132893 Resolvase Proteins 0.000 claims description 5
- 230000000843 anti-fungal effect Effects 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 108010031071 cholera toxoid Proteins 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 5
- 108010040473 pneumococcal surface protein A Proteins 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 229960000814 tetanus toxoid Drugs 0.000 claims description 5
- 229960001005 tuberculin Drugs 0.000 claims description 5
- 101150004840 uspA gene Proteins 0.000 claims description 5
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 4
- 150000004043 trisaccharides Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 184
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 30
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 15
- 229920000136 polysorbate Polymers 0.000 description 15
- 229950008882 polysorbate Drugs 0.000 description 15
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 239000008240 homogeneous mixture Substances 0.000 description 10
- 241000282412 Homo Species 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000028993 immune response Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- YXVHVBFCVDBUMB-UHFFFAOYSA-N acetic acid 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O YXVHVBFCVDBUMB-UHFFFAOYSA-N 0.000 description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 5
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical group O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 5
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000008241 heterogeneous mixture Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 239000008057 potassium phosphate buffer Substances 0.000 description 5
- 229940071643 prefilled syringe Drugs 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- -1 sorbitan ester Chemical class 0.000 description 5
- 239000008223 sterile water Substances 0.000 description 5
- 239000008362 succinate buffer Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- KVLCHQHEQROXGN-UHFFFAOYSA-N aluminium(1+) Chemical compound [Al+] KVLCHQHEQROXGN-UHFFFAOYSA-N 0.000 description 4
- 229940007076 aluminum cation Drugs 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229910017053 inorganic salt Inorganic materials 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022111088A JP2022130741A (ja) | 2016-03-31 | 2022-07-11 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2023152185A JP2023166591A (ja) | 2016-03-31 | 2023-09-20 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2025095460A JP2025124888A (ja) | 2016-03-31 | 2025-06-09 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316555P | 2016-03-31 | 2016-03-31 | |
| US62/316,555 | 2016-03-31 | ||
| US201662330245P | 2016-05-02 | 2016-05-02 | |
| US62/330,245 | 2016-05-02 | ||
| US201662372263P | 2016-08-08 | 2016-08-08 | |
| US62/372,263 | 2016-08-08 | ||
| US201662373807P | 2016-08-11 | 2016-08-11 | |
| US62/373,807 | 2016-08-11 | ||
| PCT/US2017/025621 WO2017173415A2 (en) | 2016-03-31 | 2017-03-31 | Saccharide-polypeptide conjugate compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022111088A Division JP2022130741A (ja) | 2016-03-31 | 2022-07-11 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513821A JP2019513821A (ja) | 2019-05-30 |
| JP2019513821A5 true JP2019513821A5 (enExample) | 2020-05-14 |
| JP7164200B2 JP7164200B2 (ja) | 2022-11-01 |
Family
ID=59965349
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019502538A Active JP7164200B2 (ja) | 2016-03-31 | 2017-03-31 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2022111088A Revoked JP2022130741A (ja) | 2016-03-31 | 2022-07-11 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2023152185A Pending JP2023166591A (ja) | 2016-03-31 | 2023-09-20 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2025095460A Pending JP2025124888A (ja) | 2016-03-31 | 2025-06-09 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022111088A Revoked JP2022130741A (ja) | 2016-03-31 | 2022-07-11 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2023152185A Pending JP2023166591A (ja) | 2016-03-31 | 2023-09-20 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
| JP2025095460A Pending JP2025124888A (ja) | 2016-03-31 | 2025-06-09 | サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11058757B2 (enExample) |
| EP (2) | EP4488286A3 (enExample) |
| JP (4) | JP7164200B2 (enExample) |
| WO (1) | WO2017173415A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017173415A2 (en) * | 2016-03-31 | 2017-10-05 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| US11998599B2 (en) * | 2016-12-30 | 2024-06-04 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| GB201711637D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB201711635D0 (en) * | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| KR102734995B1 (ko) | 2017-09-07 | 2024-11-26 | 머크 샤프 앤드 돔 엘엘씨 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| RS65893B1 (sr) * | 2017-09-07 | 2024-09-30 | Merck Sharp & Dohme Llc | Pneumokokni polisaharidi i njihova primena u imunogenim konjugatima polisaharid-proteinski nosač |
| AU2018328036B2 (en) | 2017-09-07 | 2024-03-07 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| KR102736151B1 (ko) | 2017-09-07 | 2024-11-28 | 머크 샤프 앤드 돔 엘엘씨 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| WO2019070994A1 (en) * | 2017-10-04 | 2019-04-11 | Liffey Biotech Limited | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE |
| UA128603C2 (uk) * | 2017-12-06 | 2024-08-28 | Мерк Шарп Енд Доум Елелсі | Полівалентна імуногенна композиція проти пневмококового захворювання |
| KR20230008923A (ko) | 2018-02-05 | 2023-01-16 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| JP2021522213A (ja) | 2018-04-18 | 2021-08-30 | エスケー バイオサイエンス カンパニー リミテッド | ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体 |
| ES2989087T3 (es) * | 2018-07-04 | 2024-11-25 | Vaxcyte Inc | Mejoras en conjugados inmunogénicos |
| MX2021003358A (es) * | 2018-09-23 | 2021-05-27 | Biological E Ltd | Polisacaridos capsulares purificados de streptococcus pneumoniae. |
| US20220143166A1 (en) * | 2018-10-12 | 2022-05-12 | Biological E Limited | Multivalent pneumococcal polysaccharide-protein conjugate vaccine |
| WO2020121159A1 (en) * | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| SG11202106541WA (en) * | 2018-12-19 | 2021-07-29 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2020208502A1 (en) * | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| MX2021014948A (es) * | 2019-06-05 | 2022-01-24 | Merck Sharp & Dohme Llc | Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae. |
| JP7630603B2 (ja) * | 2020-08-10 | 2025-02-17 | インベントプライズ・インコーポレイテッド | 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン |
| WO2022097010A1 (en) * | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| CN115671274B (zh) * | 2022-09-29 | 2024-03-12 | 普大生物科技(泰州)有限公司 | 一种载体蛋白与多糖共价键连接成结合物的方法及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221906A (en) | 1979-03-19 | 1980-09-09 | American Cyanamid Company | Stabilization of pneumococcal polysaccharides |
| US4242501A (en) | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| US4686102A (en) | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| JP4057576B2 (ja) | 2004-10-08 | 2008-03-05 | 財団法人浜松科学技術研究振興会 | 靴底用中敷 |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| BRPI0715396B8 (pt) * | 2006-08-07 | 2021-05-25 | Harvard College | método de produção de uma composição para vacina |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| ITMI20130142A1 (it) * | 2013-01-31 | 2014-08-01 | Biosynth Srl | Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati |
| ES2959258T3 (es) | 2013-02-07 | 2024-02-22 | Childrens Medical Center | Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas |
| CN104069488A (zh) * | 2013-03-29 | 2014-10-01 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法 |
| EP3019522B1 (en) | 2013-07-10 | 2017-12-13 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| KR20160040556A (ko) | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
| MY191539A (en) | 2015-03-26 | 2022-06-30 | Gpn Vaccines Pty Ltd | Streptococcal vaccine |
| MX389480B (es) | 2015-06-23 | 2025-03-20 | Biological E Ltd | Vacuna conjugada neumococica polivalente. |
| IL303998A (en) | 2015-07-21 | 2023-08-01 | Pfizer | Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2017173415A2 (en) * | 2016-03-31 | 2017-10-05 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
| EP3518965A1 (en) * | 2016-09-30 | 2019-08-07 | Biological E Limited | Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates |
| WO2019070994A1 (en) * | 2017-10-04 | 2019-04-11 | Liffey Biotech Limited | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE |
-
2017
- 2017-03-31 WO PCT/US2017/025621 patent/WO2017173415A2/en not_active Ceased
- 2017-03-31 JP JP2019502538A patent/JP7164200B2/ja active Active
- 2017-03-31 US US16/089,040 patent/US11058757B2/en active Active
- 2017-03-31 EP EP24193141.9A patent/EP4488286A3/en active Pending
- 2017-03-31 EP EP17776881.9A patent/EP3436061A4/en not_active Withdrawn
-
2021
- 2021-06-14 US US17/347,435 patent/US20220143167A1/en active Pending
-
2022
- 2022-07-11 JP JP2022111088A patent/JP2022130741A/ja not_active Revoked
-
2023
- 2023-09-20 JP JP2023152185A patent/JP2023166591A/ja active Pending
-
2025
- 2025-06-09 JP JP2025095460A patent/JP2025124888A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513821A5 (enExample) | ||
| US12295998B2 (en) | Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates | |
| JP7690523B2 (ja) | 多価肺炎球菌多糖体－タンパク質複合体組成物 | |
| KR102225282B1 (ko) | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 | |
| Khatun et al. | An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity | |
| AU2019215212B2 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| JP2022105155A (ja) | 多糖類－タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物 | |
| ES2546186T3 (es) | Procedimiento de fabricación de vacunas | |
| JP2020533439A5 (enExample) | ||
| CN103402544A (zh) | 缀合方法 | |
| MX2012010388A (es) | Proceso de conjugacion de polisacaridos bacterianos con proteinas portadoras. | |
| JP2018516962A5 (enExample) | ||
| KR20130098362A (ko) | 면역원성 조성물 | |
| JP2018518512A (ja) | 多価肺炎球菌コンジュゲートワクチン | |
| Lockhart | Conjugate vaccines | |
| BR112015016817B1 (pt) | métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica | |
| Ahmad et al. | Conjugated polysaccharide vaccines | |
| KR20200018784A (ko) | 신규 다가 다당류-단백질 접합체 백신 조성물 및 이의 제형 | |
| EP3817775B1 (en) | Improvements in immunogenic conjugates | |
| CA3155669A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| RU2023120100A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| RU2020112314A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| HK40023130B (zh) | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 | |
| HK40050310B (en) | Improvements in immunogenic conjugates | |
| HK40050310A (en) | Improvements in immunogenic conjugates |